BioProgress agrees in-licensing of MuGard from Access Pharmaceuticals

Published: 8-Feb-2007
Regulatory

UK speciality pharmaceutical and healthcare company BioProgress has agreed, subject to final contract, to in-license MuGard from US-based Access Pharmaceuticals.


UK speciality pharmaceutical and healthcare company BioProgress has agreed, subject to final contract, to in-license MuGard from US-based Access Pharmaceuticals.

MuGard is a proprietary mucoadhesive polymer oral rinse product, currently approved as a medical device in the US for the management of oral mucositis, a painful inflammatory mouth condition that afflicts more than 40% of cancer patients undergoing chemotherapy and radiation therapy.

As consideration for the exclusive rights, BioProgress will, upon signing the final licensing agreement, pay Access $1m. In addition to the exclusive license it has also been agreed that BioProgress will be responsible for the manufacturing of the product and product line extensions using its enabling system, for example, SoluPol. Access has assumed the payment of agreed manufacturing and scale-up costs prior to product launch.

MuGard, which will be launched in the second half of this year, will be promoted to cancer treatment centres as a prescription medicine. BioProgress will be marketing the product within the European, CIS and Middle East regions.

In addition to the management of mucositis, the approved indication for MuGard includes all types of oral wounds, including aphthous ulcers and traumatic ulcers, such as those caused by oral surgery or ill-fitting dentures or braces. The broad-based approval provides BioProgress with the opportunity to promote the use of the product for several related oral ulcerative conditions.

'BioProgress is continuing to build its portfolio of products within its patient supportive care franchise and MuGard offers a real treatment for a painful condition that is poorly managed,' said Steve Martin, chief development officer, BioProgress.

'In line with the company's other developments in this area, we see this as a robust step to gaining critical mass within one of our niche and growing areas of expertise. BioProgress will continue to build on the MuGard concept with Access to offer a wider range of delivery systems for the patient.'

  • Companies:
  • Meldex International PLC
See more

You may also like

Regulatory

Broughton receives flexible scope ISO 17025 accreditation

Read more
New certification allows accreditation without prior approval

Trending Articles

  1. Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for successful market entry from the early stages of development, reports Frederick Duynslaeger, Senior CMC Writer at Ardena
  2. Overcoming CMC challenges in cell and gene therapy: part II Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
  3. Overcoming CMC challenges in cell and gene therapy: part I Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
  4. Innovating with purpose for safety and security of outcome Beyond the importance of increasing productivity and generating more output and value with the same input, new ideas and technologies from GEA take innovation a step further
  5. AskBio receives FDA Fast Track Designation for congestive heart failure gene therapy programme The fast-tracking allows the development and expedition of review processes for AB-1002, a gene therapy to promote production of a constituently active form of I-1c

Upcoming event

Cleanroom Conference UK

22–23 May 2024 | Exhibition | Birmingham, UK See all

You may also like

Regulatory

Broughton receives flexible scope ISO 17025 accreditation

New certification allows accreditation without prior approval
Regulatory

Overcoming CMC challenges in cell and gene therapy: part II

Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
Regulatory

Overcoming CMC challenges in cell and gene therapy: part I

Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
Regulatory

AskBio receives FDA Fast Track Designation for congestive heart failure gene therapy programme

The fast-tracking allows the development and expedition of review processes for AB-1002, a gene therapy to promote production of a constituently active form of I-1c
Manufacturing

Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success

Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for successful market entry from the early stages of development, reports Frederick Duynslaeger, Senior CMC Writer at Ardena
Regulatory

Isospec Analytics launches biomolecular analysis technology to identify unknown molecules

The novel technology optimises the identification process of unknown molecules compared to mass analysis
Regulatory

4SC AG receives Paediatric Investigation Plan waiver for resminostat from the UK MHRA

The waiver allows the company to avoid investigating the CTCL drug in a paediatric population, as it's considered unnecessary or inappropriate for use by this patient group
Subscribe now